Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTechnische Universität Dresden

About this trial

The aim is rapid collection of real-life data on the epidemiology, treatment and disease course in patients with VEXAS syndrome during routine clinical practice and collect biomaterials to evaluate genotype-phenotype associations, determine optimal treatment schedule, identify diagnostic features and biomarkers

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with established or suspected (clinical and hematological criteria) VEXAS Syndrome

Age ≥18 years

Signed informed consent form

Disqualifiers

patients who are not in a position to understand the nature and scope of participation in this register

Trial population

* Planned recruitment: 20-30 patients/year * Number of planned study centres: 15-20

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Collection of epidemiological data on VEXAS

incidence, age and sex distribution in adults in Germany

Time frame
enrollment
2

Collection and monitoring of initial disease manifestations

* spectrum and frequency of inflammatory manifestations * Association with hematological (pre)malignancies (MDS, Myeloma, MGUS, CHIP) * Monitor cardiovascular risk/thromboembolic events

Time frame
5 years
3

Documentation of the treatment approaches and therapy sequences

Documentation of the treatment approaches and therapy sequences

Time frame
5 years
4

Analysis of clinical-relevant clinical endpoints

complete remission (CR), hematological and clinical remission, molecular remissions, treatment-free remission (TFR)

Time frame
5 years

Secondary outcomes

1

Describe disease cluster

* Phenotype cluster? * Genotype-phenotype associations? * Identification of biomarker?

Time frame
5 years
2

Laboratory diagnostics

* Establish Diagnostic FACS signature * Establish biomarker for disease monitoring * Molecular characterization of the key regulatory gene UBA1, but also accompanying molecular mutations * Correlation with HLA polymorphisms * Coagulation Diagnostics

Time frame
5 years
3

Correlation clinical endpoints with treatment approaches

Correlation clinical endpoints with treatment approaches

Time frame
5 years
4

Quality of life data (QoL), fatigue questionnaire (Facit-F)

Quality of life data (QoL), fatigue questionnaire (Facit-F)

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Technische Universität Dresden

Lead sponsor

Bristol-Myers Squibb

Collaborator

University Hospital Munich

Collaborator